SEARCH

SEARCH BY CITATION

References

  • 1
    Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013; doi: 10.1016/S0140-6736(13)60096-3.
  • 2
    Karlsen TH, Boberg KM. Update on primary sclerosing cholangitis. J Hepatol. 2013;59:571582.
  • 3
    Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:15901599.
  • 4
    Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan—analysis of 192 cases. J Gastroenterol. 1997;32:134137.
  • 5
    Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res. 2004;29:153159.
  • 6
    Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610615.
  • 7
    Farrant J, Hayllar K, Wilkinson M, Karani J, Portmann B, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Ganstroenterology. 1991;100:17101717.
  • 8
    Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kolmannskog F. Risk factors in primary sclerosing cholangitis. J Hepatol. 1994;21:10611066.
  • 9
    Wiesner R, Grambsch P, Dickson E, Ludwig J, MacCarty R, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10:430436.
  • 10
    Hamano H, Kawa S, Uehara T, Ochi Y, Takayama M, Komatsu K, et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc. 2005;62:152157.
  • 11
    Uehara T, Hamano H, Kawa S, Sano K, Honda T, Ota H. Distinct clinicopathological entity “autoimmune pancreatitis-associated sclerosing cholangitis”. Pathol Int. 2005;55:405411.
  • 12
    Zen Y, Harada K, Sasaki M, Sato Y, Tsuneyama K, Haratake J, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol. 2004;28:11931203.
  • 13
    Hamano H, Umemura T, Uehara T, Kawa S, Kiyosawa K. IgG4-related sclerosing cholangitis should be included as an exclusion criterion for the diagnosis of primary sclerosing cholangitis. Am J Gastroenterol. 2007;102:691692.
  • 14
    Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536542.
  • 15
    Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H. A nation-wide survey of sclerosing cholangitis. Tando. 2013;27:176187 (in Japanese with English abstract).
  • 16
    Lindor K, LaRusso N. Primary sclerosing cholangitis. In: Schiff E , editor. Schiff's disease of the liver, 10th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 673684.
  • 17
    Nakazawa T, Ohara H, Sano H, Ando T, Joh T. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas. 2006;32:229.
  • 18
    Kaplan G, Laupland K, Butzner D, Urbanski S, Lee S. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:10421049.
    Direct Link:
  • 19
    Tanaka A. The epidemiological study of PSC in Japan. Health Labour Sciences Research Grant from Research on Measures for Intractable Diseases, the intractable hepato-biliary disease study group in Japan. 2008 [in Japanese].
  • 20
    Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun. 2013; doi: 10.1016/j.jaut.2013.07.005.
  • 21
    Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:13641369.
  • 22
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99103.
  • 23
    Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology. 2013; doi: 10.1002/hep.26565.
  • 24
    Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48:939944.
  • 25
    Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21:787791.
  • 26
    Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:19291930.
  • 27
    Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571577.
  • 28
    Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol. 2002;17:908913.
  • 29
    Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706715.